# EDGAR Filing Document

**Accession Number:** 0000072444
**File Stem:** 0000921895-25-002488
**Filing Date:** 2025-9
**Character Count:** 6624
**Document Hash:** 27edd73e506effaaf3107a3b5719b843
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002488.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0000921895-25-002488

**CONFORMED SUBMISSION TYPE**: PX14A6G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**EFFECTIVENESS DATE**: 20250902

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaxart, Inc.
- **CENTRAL INDEX KEY:** 0000072444
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 591212264
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** PX14A6G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35285
- **FILM NUMBER:** 251284523

**BUSINESS ADDRESS:**
- **STREET 1:** 170 HARBOR WAY, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 550-3500

**MAIL ADDRESS:**
- **STREET 1:** 170 HARBOR WAY, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aviragen Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biota Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20121113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NABI BIOPHARMACEUTICALS
- **DATE OF NAME CHANGE:** 20100719
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Houle Daniel P
- **CENTRAL INDEX KEY:** 0002083372

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** PX14A6G

**MAIL ADDRESS:**
- **STREET 1:** C/O OLSHAN FROME WOLOSKY LLP
- **STREET 2:** 1325 AVENUE OF THE AMERICAS
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**NOTICE OF EXEMPT SOLICITATION**

Submitted Pursuant to Rule 14a-6(g)

**(Amendment No. <u>_</u>)**

1. Name of the Registrant:

Vaxart, Inc.

2. Name of Person Relying on Exemption:

Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders")

3. Address of Person Relying on Exemption:

Concerned Vaxart Stockholders<br> c/o Olshan Frome Wolosky LLP<br> 1325 Avenue of the Americas<br> New York, NY 10019

4. Written Materials. The following written material is attached hereto:

Press release, dated September 2, 2025.

\* \* \*

Written material is submitted voluntarily pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. **The soliciting persons do not beneficially own more than $5 million of the class of subject securities of the Issuer and the notice is therefore being provided on a voluntary basis**.

This is not a solicitation of authority to vote any proxy. The Concerned Vaxart Stockholders are not asking for your proxy card and will not accept proxy cards if sent. The cost of this filing is being borne entirely by the Concerned Vaxart Stockholders.

**PLEASE NOTE: The Concerned Vaxart Stockholders are not asking for your proxy card and cannot accept your proxy card. Please DO NOT send us your proxy card.**

*(Written material follows on next page)*

**Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote "AGAINST" Reverse Stock Split and Demand Board Accountability**

***Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition***

**ATLANTA, September 2, 2025** – Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.5 million shares of Vaxart, Inc. (OTC: VXRT) ("Vaxart" or the "Company") today urged fellow stockholders to vote "**<u>AGAINST</u>**" the Company's proposed reverse stock split at the upcoming special meeting of stockholders scheduled to be held on September 5, 2025 (the "Special Meeting").

Despite clear and repeated stockholder opposition, the Company's board of directors (the "Board") is once again seeking stockholder approval for a reverse stock split. At the Company's June 13, 2025 annual meeting of stockholders (the "2025 Annual Meeting"), stockholders emphatically rejected a reverse stock split proposal and withheld support from a majority of the Board, including Chairman Dr. Michael Finney. Nevertheless, the full Board remains in place and is once again advancing a reverse stock split proposal, disregarding the will of stockholders.

At the 2025 Annual Meeting, **<u>stockholders decisively rejected the reverse stock split proposal, with a clear majority of 59.1% voting "AGAINST."</u>** In addition, **<u>four of the six directors on the ballot failed to secure majority support</u>**:

&nbsp;&nbsp;&nbsp;&nbsp;· **Dr. Michael Finney (Chairman)**: 51.5% "WITHHELD" (58,278,600 votes) vs. 48.5% "FOR"
(54,978,926 votes)

&nbsp;&nbsp;&nbsp;&nbsp;· **Steven Lo (CEO)**: 50.5% "WITHHELD" (57,202,309 votes) vs. 49.5% "FOR" (56,055,217
votes)

&nbsp;&nbsp;&nbsp;&nbsp;· **Dr. David Wheadon**: 59% "WITHHELD" (66,780,752 votes) vs. 41% "FOR" (46,476,774
votes)

&nbsp;&nbsp;&nbsp;&nbsp;· **Dr. Elaine Heron**: 50.9% "WITHHELD" (57,683,960 votes) vs. 49.1% "FOR" (55,573,566
votes)

These numbers, which represent the voice of stockholders, speak volumes. Stockholders have repeatedly expressed a lack of confidence in the Board. Yet, the Board continues to act unilaterally, ignore the will of the Company's investors and insists on pursuing what we view as a value-destructive course of action. We are concerned that a reverse stock split at this time would only reduce liquidity, increase volatility and potentially mask deeper structural issues. We believe this proposal is not in the best interest of long-term stockholders.

It is time for stockholders to unite and demand accountability. The Concerned Vaxart Stockholders urge all fellow stockholders to vote **"<u>AGAINST</u>" the reverse stock split proposal at the upcoming Special Meeting**.

Sincerely,

The Concerned Vaxart Stockholders

**THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD. THE CONCERNED VAXART STOCKHOLDERS ARE NOT ASKING FOR YOUR PROXY CARD AND WILL NOT ACCEPT PROXY CARDS IF SENT. THE CONCERNED VAXART STOCKHOLDERS ARE NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.**

**Contact Information**

Daniel Houle

lloyd19791@gmail.com

(518) 222-3132